ArticleCureus2025
Molecular Characterization of Patatin-Like Phospholipase Domain-Containing 3 (PNPLA3) Gene in Alcoholic Liver Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcoholic liver disease (ALD) is a significant cause of liver-related morbidity and mortality worldwide. The role of genetic factors, particularly the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, in the progression of ALD remains underexplored in the Indian population. This study aims to investigate the molecular characterization of the PNPLA3 gene polymorphism in individuals with ALD in India. MATERIALS AND
methodsA cross-sectional study was conducted at Bharatiya Lingayat Development Educational Association (BLDE) (Deemed to Be University), Shri B. M. Patil Medical College Hospital and Research Center, Vijayapura, from May 2023 to December 2024. The study involved 60 patients diagnosed with ALD, confirmed through clinical history, radiological findings, and biochemical parameters. Genetic analysis for PNPLA3 polymorphism was performed using polymerase chain reaction (PCR)-based molecular techniques, and DNA sequencing was carried out to detect the rs738409 and rs738408 mutations. Data analysis was performed using SPSS version 26 (IBM Corp., Armonk, NY), and descriptive statistics and independent sample t-tests were used for comparisons.
resultsAmong the 60 study participants, the majority were male 58(96.7%), with a mean age of 41-50 years. The most common disease stage was cirrhosis, 42(70%). Genetic analysis revealed that 49(81.7%) of participants had no detectable mutation, while 5(8.3%) had the rs738409 polymorphism, and 6(10%) had both rs738409 and rs738408 mutations. No significant associations were found between the genetic mutations and demographic or clinical variables. However, laboratory analyses showed significantly higher aspartate aminotransferase (AST) levels and lower leukocyte and platelet counts in mutation-positive individuals compared to those without mutations.
conclusionsThe study identified the presence of PNPLA3 genetic mutations in a small subset of patients with ALD in India. Although the mutations did not show significant associations with demographic or clinical variables, they were associated with altered laboratory parameters, highlighting the potential role of PNPLA3 in the progression of ALD. Further studies are required to validate these findings and understand the genetic basis of ALD in the Indian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.